Elevated levels of YTHDF1 and YTHDF2 correlate with a good survival outlook, more tumour‐infiltrating lymphocytes and PD‐L1 down‐regulation in NSCLC patients, suggesting their potential as prognostic markers and therapeutic targets related to the TIME in lung cancer.187. This evidence concerns the gene YTHDF1 and lung carcinoma.